Patents Assigned to Amgen
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Publication number: 20070072801
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: August 4, 2006
    Publication date: March 29, 2007
    Applicant: AMGEN INC.
    Inventors: Jonathan Oliner, Hosung Min
  • Pyrazolopyridine and pyrazolopyrimidine compounds
    Publication number: 20070072851
    Abstract: The present invention relates to compounds of Formula I or a stereomer, a tautomer, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof, pharmaceutical formulations containing the compounds, methods of treatments using the compounds, for example, protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders and methods of preparing medicaments comprising the compounds.
    Type: Application
    Filed: August 18, 2006
    Publication date: March 29, 2007
    Applicant: Amgen Inc.
    Inventors: John Buchanan, William Buckner, Mario Cardozo, Erin DiMauro, Jiasheng Fu, Xiaolin Hao, Xian Jiao, Frank Kayser, David Kopecky, Craig Masse, Susan Tomlinson, Ryan White, Xiaotian Zhu
  • Epitopes
    Publication number: 20070072797
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Application
    Filed: April 25, 2006
    Publication date: March 29, 2007
    Applicants: UCB S.A., Amgen, Inc.
    Inventors: Martyn Robinson, Alistair Henry, Alastair Lawson, Hsieng Lu, Christopher Paszty, Kelly Hoffmann, John Latham, David Winkler, Aaron Winters
  • Thiazolyl urea compounds and methods of uses
    Patent number: 7196104
    Abstract: Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: March 27, 2007
    Assignee: Amgen, Inc.
    Inventors: Benny C. Askew, Jr., Frenel F. De Morin, Andrew Hague, Ellen Laber, Aiwen Li, Gang Liu, Patricia Lopez, Rana Nomak, Vincent Santora, Christopher Tegley, Kevin Yang
  • Phosphatases which activate map kinase pathways
    Patent number: 7195902
    Abstract: The present invention provides novel JNK activating phosphatase polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing JNK activating phosphatase polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with JNK activating phosphatase polypeptides.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: March 27, 2007
    Assignees: Amgen Corporation, Baylor College of Medicine
    Inventors: John W. Belmont, Frederick A. Fletcher, Alice J. Chen, Roland Jurecic, Tse-Hua Tan, Guisheng Zhou
  • Methods for the treatment of thrombosis
    Patent number: 7195903
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: March 27, 2007
    Assignee: Amgen, Inc.
    Inventors: Thomas C. Boone, Huimin Li, Michael B. Mann
  • Calcium receptor modulating agents
    Patent number: 7196102
    Abstract: The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: March 27, 2007
    Assignee: Amgen Inc.
    Inventors: Michael G. Kelly, Shimin Xu, Ning Xi, Philip Miller, John F. Kincaid, Chiara Ghiron, Thomas Coulter
  • Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
    Publication number: 20070066647
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L1, L2, M, X, L3, and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: September 8, 2006
    Publication date: March 22, 2007
    Applicant: AMGEN ING.
    Inventors: Michelle Akerman, Sean Brown, Jonathan Houze, Jinqian Liu, Jiwen Liu, Zhihua Ma, Julio Medina, Wei Qiu, Michael Schmitt, Rajiv Sharma, Yingcai Wang, Liusheng Zhu
  • Human monoclonal antibodies to activin receptor-like kinase-1
    Publication number: 20070065444
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Application
    Filed: September 6, 2006
    Publication date: March 22, 2007
    Applicants: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Michael North, Karin Amundson, Vahe Bedian, Shelley Belouski, Dana Hu-Lowe, Xin Jiang, Shannon Karlicek, Sirid Kellermann, James Thomson, Jianying Wang, Grant Wickman, Jingchuan Zhang
  • IL-17 receptor like molecules and uses thereof
    Publication number: 20070065868
    Abstract: Novel IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
    Type: Application
    Filed: November 2, 2006
    Publication date: March 22, 2007
    Applicant: AMGEN INC.
    Inventor: Shuqian Jing
  • Polynucleotides encoding epithelium-derived T-cell factor and uses thereof
    Patent number: 7192935
    Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: March 20, 2007
    Assignee: Amgen Inc.
    Inventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
  • Methods of modulating intestinal fluid balance
    Publication number: 20070060625
    Abstract: The present invention relates to methods for treating or preventing intestinal fluid balance disorders and modulating intestinal fluid secretion and absorption using calcimimetics and calcilytics.
    Type: Application
    Filed: August 28, 2006
    Publication date: March 15, 2007
    Applicants: Amgen Inc., John Peter Geibel, Steven Charles Hebert
    Inventors: John Geibel, Steven Hebert, David Martin, Deborah Russell
  • Modified peptides as therapeutic agents
    Patent number: 7189827
    Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: March 13, 2007
    Assignee: Amgen Inc.
    Inventor: Ulrich Feige
  • Receptor ligands and methods of modulating receptors
    Patent number: 7189524
    Abstract: The invention provides natural ligands of TGR183 receptors and methods of identifying modulators of various TGR183 receptors using the ligands. Methods of using the modulators to treat diseases or disorders associated with dysfunction of the TGR183 receptor are also provided.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: March 13, 2007
    Assignee: Amgen, Inc.
    Inventors: Songzhu An, Jin-Long Chen, Hui Tian, Wendy Wen Zhong
  • Bis-aryl kinase inhibitors and method
    Publication number: 20070054903
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: June 30, 2006
    Publication date: March 8, 2007
    Applicant: Amgen Inc.
    Inventors: Tae-Seong Kim, Jean-Christophe Harmange, Steven Bellon, Shon Booker, Noel D'Angelo, Celia Dominguez, Ingrid Fellows, Julie Germain, Timothy Harvey, Joseph Kim, Matthew Lee, Longbin Liu, Vinod Patel, Andrew Tasker
  • Pharmaceutical formulations
    Publication number: 20070053871
    Abstract: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
    Type: Application
    Filed: August 4, 2006
    Publication date: March 8, 2007
    Applicant: AMGEN INC.
    Inventors: Tiansheng Li, Christopher Sloey
  • Antiinflammation agents
    Patent number: 7186841
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain fused carbocyclic or heterocyclic rings.
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: March 6, 2007
    Assignees: Amgen Inc., Syntex (U.S.A.) LLC
    Inventors: Michelle F. Browner, David L. Clark, Timothy D. Cushing, Xiaolin Hao, Ronald C. Hawley, Xiao He, Juan C. Jaen, Sharada S. Labadie, Marie-Louise Smith, Francisco X. Talamas, Nigel P. C. Walker, Marc Labelle
  • Modified peptides as therapeutic agents
    Patent number: 7186810
    Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: March 6, 2007
    Assignee: Amgen Inc.
    Inventor: Ulrich Feige
  • Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
    Patent number: 7183254
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: February 27, 2007
    Assignee: Amgen, Inc.
    Inventors: Alexander M. DePaoli, Simeon I. Taylor, Elif A. Oral, Abhimanyu Garg
  • Human E3? ubiquitin ligase family
    Patent number: 7179625
    Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: February 20, 2007
    Assignee: Amgen Inc.
    Inventors: Hui-Quan Han, Keith Kwak